ABBV-295 Phase 1 topline obesity results [developing]
Key Questions
What are the key Phase 1 topline results for ABBV-295 in obesity?
In the multiple ascending dose (MAD) portion of the Phase 1 trial, ABBV-295 demonstrated 8-10% weight loss. Topline results are expected around March 15, 2026.
What is the analyst outlook for ABBV-295?
Analyst Blair is bullish on ABBV-295. Declining hype around GLP-1 competitors could aid its market entry, though the Phase 2 bar remains high.
How does ABBV-295 position itself in the obesity market?
ABBV-295 targets obesity amid GLP-1 competitors like semaglutide, where hype is cracking, potentially easing entry. Its development status is ongoing, with Phase 2 expectations set high.
MAD 8–10% WL (2026-03-15), Blair bullish. GLP-1 comps hype cracks aid entry; Ph2 bar high.
Sources (2)
Updated Apr 8, 2026